All In Biotech

NDA 213983 · Viiv Hlthcare

Tivicay Pd

Dolutegravir Sodium · Oral

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 12, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

306

91 Phase 3, 30 recruiting

FAERS reports

758

730 serious, 174 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 25, 2026.

TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV ‑ 1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor [INSTI]-naïve) weighing at least 2 kg [see Microbiology ( 12.4 )] . TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. TIVICAY and TIVICAY PD are an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but INSTI- naïve) weighing at least 2 kg. ( 1 ) TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. ( 1 )

Mechanism: Dolutegravir is an HIV-1 antiretroviral agent [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 25, 2026 Supplement 7 · Efficacy · priority review LetterLabel
  • Jul 9, 2021 Supplement 2 · Efficacy LabelLetter
  • Jun 12, 2020 Original approval · Type 3 - New Dosage Form · priority review LabelLetterReview
1 products under this application
  • TIVICAY PD · DOLUTEGRAVIR SODIUM EQ 5MG BASE · TABLET, FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dolutegravir" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • exposure during pregnancy399
  • off label use331
  • headache324
  • immunodeficiency322
  • hyperhidrosis321
  • hypertension320
  • hepatic enzyme increased319
  • joint swelling319
  • food allergy316
  • pyrexia314
  • asthma311
  • hypersensitivity311

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20152
20164
20174
201822
201916
202029
202160
202254
2023191
2024222
202598
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tivicay Pd (Dolutegravir Sodium)

2024 spending

$38K

Beneficiaries

n/a

35 claims

Per beneficiary

n/a

$7.07 per unit

View as table
YearSpending
2020$0
2021$22,430
2022$24,727
2023$35,827
2024$37,772

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 435 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.